Blood reviewsHumansMultiple MyelomaAntibodiesBispecificAntineoplastic Agents
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies.
Xiang Zhou, Johannes M Waldschmidt, Hermann Einsele
Published: 202510.1016/j.blre.2025.101342
Abstract
Bispecific antibodies have emerged as a transformative immunotherapeutic strategy in multiple myeloma (MM). Early constructs such as BiTEs paved the way for full-length IgG-based antibodies with improved pharmacokinetics and safety profiles. As of 20…
Preview only. Read the full abstract at the source